A 52-year-old woman from Delhi presents with a 3-month history of dysphagia and a painless swelling in the right lateral pharyngeal wall. She denies tobacco or alcohol use. On examination, a 3 cm × 2.5 cm indurated, ulcerated lesion is visible on the right lateral oropharyngeal wall. The lesion appears to involve the soft palate and lateral pharyngeal wall. Biopsy confirms squamous cell carcinoma. MRI shows tumor extension into the lateral pharyngeal space and involvement of the right lateral pterygoid muscle. Cervical lymph nodes are not clinically palpable. What is the most appropriate next step in management?

Explanation

## Management of Oropharyngeal Carcinoma with Pterygoid Involvement ### Staging and Extent of Disease **Key Point:** This patient has: - **Tumor size:** 3 cm × 2.5 cm (T2 or T3 depending on depth) - **Pterygoid muscle involvement:** This indicates **T4a disease** (moderately advanced local disease with invasion of muscles of mastication) - **N0 disease:** No palpable cervical lymphadenopathy - **M0:** No distant metastasis This represents **Stage IVA disease** (T4a N0 M0). ### Treatment Algorithm for T4a Oropharyngeal Carcinoma ```mermaid flowchart TD A[T4a N0-N3 Oropharyngeal SCC]:::outcome --> B{Resectable?}:::decision B -->|Yes, good PS| C[Surgery + Neck Dissection]:::action C --> D{Adverse features?}:::decision D -->|Yes: PNI, LVI, margins| E[Adjuvant CCRT]:::action D -->|No| F[Observation or RT]:::action B -->|No or poor PS| G[CCRT]:::action G --> H[Response assessment at 8-12 weeks]:::action H --> I[Complete response: Surveillance]:::outcome H --> J[Partial/No response: Salvage surgery]:::urgent ``` ### Rationale for Concurrent Chemoradiotherapy **High-Yield:** CCRT is the standard of care for: 1. **Unresectable T4a disease** (pterygoid involvement often makes surgical resection morbid or impossible) 2. **N+ disease** (improves locoregional control and overall survival) 3. **High-risk features** (PNI, LVI, poor differentiation) **Clinical Pearl:** Pterygoid muscle involvement is a relative contraindication to transoral approaches due to: - Difficulty achieving adequate margins - High risk of residual disease - Increased morbidity from wide resection ### Why CCRT Over Radiotherapy Alone | Feature | RT Alone | CCRT | |---------|----------|------| | **Locoregional control (3-yr)** | 50–60% | 70–80% | | **Overall survival (3-yr)** | 40–50% | 60–70% | | **Toxicity** | Moderate | Higher (mucositis, dysphagia) | | **Indication** | Early stage, poor PS | Locally advanced, good PS | **Mnemonic: CCRT for T4 = Concurrent Chemotherapy Reduces Tumor (burden and recurrence)** ### Why Other Options Are Suboptimal **Option A (RT alone):** Inferior locoregional control and survival for T4a disease compared to CCRT in patients with adequate performance status. **Option B (TLM + adjuvant RT):** Pterygoid involvement makes transoral resection technically unfeasible and risks incomplete resection. TLM is suited for early T-stage, accessible lesions. **Option D (Palliative chemotherapy):** Reserved for metastatic disease or patients unfit for curative intent therapy. This patient has no evidence of distant metastasis and should be offered curative treatment. ### Cisplatin Dosing in CCRT **Key Point:** Standard regimen is **cisplatin 100 mg/m² IV on days 1, 22, and 43** of concurrent radiotherapy (70 Gy in 35 fractions over 7 weeks). [cite:NCCN Head and Neck Cancer Guidelines 2023; Harrison 21e Ch 82]